(NASDAQ: SPTX) Seaport Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.5%.
Seaport Therapeutics's earnings in 2026 is N/A.On average, 4 Wall Street analysts forecast SPTX's earnings for 2026 to be -$183,186,895, with the lowest SPTX earnings forecast at -$205,642,961, and the highest SPTX earnings forecast at -$156,817,746. On average, 4 Wall Street analysts forecast SPTX's earnings for 2027 to be -$136,775,908, with the lowest SPTX earnings forecast at -$152,658,422, and the highest SPTX earnings forecast at -$118,034,863.
In 2028, SPTX is forecast to generate -$160,800,419 in earnings, with the lowest earnings forecast at -$204,593,762 and the highest earnings forecast at -$111,852,084.